Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$56.04
$0.54(0.97%)
At close: 4:00 PM EDT
$56.04
$0.54(0.97%)
Day’s Range― - ―
52-Week Range$26.76 - $59.30
Previous CloseN/A
Volume1.44M
Average Volume (3M)2.53M
Market Cap
$8.31B
Enterprise Value$8.84K
Total Cash (Recent Filing)$552.25M
Total Debt (Recent Filing)$754.44M
Price to Earnings (P/E)17.8
Beta0.41
Next Earnings
Nov 09, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.04
Shares Outstanding153,069,050
10 Day Avg. Volume1,944,033
30 Day Avg. Volume2,529,227
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$65.14Price Target Upside16.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.1
Revenue Forecast (FY)$955.68M
Bulls Say, Bears Say
Bulls Say
BRIUMVI Commercial GrowthRapid BRIUMVI adoption, rising patient starts and expanding physician use are establishing a stronger commercial base. The higher guidance and planned 2027 $1B+ U.S. revenue year indicate meaningful franchise momentum beyond a single quarter.
High Gross Margins And ProfitabilityThe product’s high gross margin and recent operating profitability provide operating leverage as sales expand. This supports reinvestment in commercialization and development, although reported earnings should still be assessed against weaker cash conversion.
BRIUMVI Lifecycle ExpansionA successful subcutaneous formulation could broaden BRIUMVI’s addressable market beyond physician-administered treatment and improve convenience. Alongside the positive ENHANCE trial, it may strengthen retention, switching potential and the product’s competitive longevity.
Bears Say
Weak Cash ConversionPersistent negative operating and free cash flow despite reported profitability raises questions about earnings quality, working-capital timing and cash realization. Continued weak conversion could limit internally funded investment and make reported income less durable.
Competitive And Rebate PressureRival anti-CD20 therapies can constrain market share, pricing and prescribing momentum as BRIUMVI scales. Material rebates and chargebacks further reduce realized revenue, creating a lasting risk that strong gross sales will translate into lower net economics.
Manufacturing Cost BurdenManufacturing investments for the subcutaneous and secondary-source programs are depressing reported profitability and may continue through 2026. Although they could support future supply and product expansion, execution delays would leave TG with substantial costs before benefits arrive.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $26.76 and its highest was $59.30 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $8.31B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 77 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Aug 03, 2026. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.306 by -$0.256.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.35.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,069,050 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.05 in its last earnings report, missing expectations of $0.306. Following the earnings report the stock price went down -11.263%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.14 (16.24% Upside)
$65.14 (16.24% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 96%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 178.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
133.36%
Trailing 12-Months
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
TGTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, robust Q2 financial results, multiple positive clinical/readout milestones (ENHANCE Phase III positive; subcutaneous program advancing), growing real-world evidence, and a healthy cash position — all of which underpin upgraded guidance and an optimistic multi-year franchise opportunity. Near-term headwinds include sizable manufacturing-related charges expensed now (with potential future margin tailwinds if programs succeed), seasonality/timing risk concentrated in Q4, uncertainty around subcutaneous pricing/reimbursement, and ongoing competitive dynamics. On balance, the positive operational and clinical developments and the guidance raise materially outweigh the near-term expenses and execution risks.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$65.14
▲(16.24% Upside)
Technical Analysis
Protagonist Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Legend Biotech
―
Kymera Therapeutics
―
Ownership Overview
7.54% Insiders
18.43% Mutual Funds
11.42% Other Institutional Investors
37.61% Public Companies and
Individual Investors